Revaprazan
| Title | Journal |
|---|---|
| Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers. | Clinical therapeutics 20120901 |
| Mitigating endoplasmic reticulum stress with revaprazan ameliorates stress-related mucosal disease. | Journal of gastroenterology and hepatology 20120101 |
| In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine. | Digestion 20120101 |
| The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin. | The Tohoku journal of experimental medicine 20110801 |
| Acid pump antagonist-provoked HSP27 dephosphorylation and accentuation rescues stomach from indomethacin-induced damages. | Journal of digestive diseases 20110401 |
| [Effect of acid pump antagonist (Revaprazan, Revanex(R)) on the result of 13C urea breath test in the patients with Helicobacter pylori associated peptic ulcer disease]. | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20110101 |
| [Effect of acid pump antagonist (Revaprazan, Revanex(R)) on result of 13C urea breath test in patients with Helicobacter pylori associated peptic ulcer disease]. | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20110101 |
| N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. | The Journal of pharmacology and experimental therapeutics 20090201 |
| The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. | Drug metabolism and disposition: the biological fate of chemicals 20010101 |